Statins for primary prevention of venous thromboembolism

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 12, 2014, Pages

  Li, Lun ^a   Zhang, Peizhen ^b   Tian, Jin Hui ^a   Yang, Kehu ^a  

^a LANZHOU UNIVERSITY   (China)

^b Hospital of Lanzhou City   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

BLEEDING; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG EFFICACY; ECHOGRAPHY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LUNG EMBOLISM; MORTALITY; MUSCLE RIGIDITY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; OUTCOME ASSESSMENT; PHLEBOGRAPHY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; FEMALE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; VENOUS THROMBOSIS;

FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; SULFONAMIDES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84925226159     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008203.pub3     Document Type: Review

References (110)

1. AstraZeneca. A randomized, double-blind, placebo controlled, multicenter, phase 3 study of rosuvastatin (CRESTOR®) 20 mg in the prevention of cardiovascular events among subjects with low levels of LDL cholesterol and elevated levels of C-reactive protein. http://clinicaltrials.gov/ct2/show/NCT00239681.
2. Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation 2010;121(1):143-50.
3. Fonseca FA, Izar MC. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study. Expert Review Cardiovascular Therapy 2009;7(9):1041-56.
4. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine 2009;360(18):1851-61.
5. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Annals of Internal Medicine 2010;152(8):488-96, W174.
6. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Journal of the American College of Cardiology 2011;57:1666-75.
7. Kerst AJFA. A randomised study of efficacy of statins in the prevention of venous thromboembolism. Geneesmiddelenbulletin. 2009;43:104-5.
8. Koenig W, Ridker PM. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk >/= 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. European Heart Journal 2011;32(1):75-83.
9. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010;121(9):1069-77.
10. Ridker PM, Danielson E, Fonseca F, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin in the prevention of cardiovascular events among 17, 802 men and women with elevated levels of C-reactive protein: the JUPITER trial. Circulation 2008; Vol. 118, issue 22:2310.
11. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373(9670):1175-82.
12. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine 2008;359(21):2195-207.
13. Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. American Journal of Cardiology 2007;100(11):1659-64.
14. Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010;376(9738):333-9.
15. Ridker PM, JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003;108(19):2292-7.
16. Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology 2010;55(12):1266-73.
17. Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation. Cardiovascular Quality & Outcomes 2009;2(6):616-23.
18. Ridker PM, MacFadyen JG, Nordestgaard BG, Koenig W, Kastelein JJ, Genest J, et al. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circulation. Cardiovascular Quality & Outcomes 2010;3(5):447-52.
19. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380(9841):565-71.
20. Slejko JF, Page RL, Sullivan PW. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. Current Medical Research and Opinion 2010;26(10):2485-97.
21. De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007;8:21.
22. De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, et al. Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007;8:21.
23. Downs JR, Beere PA, Whitney E, Clearfield M, Weis S, Rochen J, et al. Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology 1997;80(3):287-93.
24. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279(20):1615-22.
25. Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology 2013;62(17):1575-9.
26. Boden W, E, Probstfield J, L. Extended-release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL-cholesterol is optimally controlled with statin therapy: Results from the AIM-HIGH trial. Circulation 2011;124(21):2370.
27. Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, et al. Relation of lipoprotein levels to cardiovascular events in the atherothrombosis intervention in metabolic syndrome with low HDL/high triglyceride and impact on global health outcomes (AIM-HIGH) trial. Circulation 2012;126(21 Suppl 1):A14501.
28. Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology 2013;62:1580-4.
29. Teo KK, Goldstein LB, Chaitman BR, Grant S, Weintraub WS, Anderson, et al. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke 2013;44(10):2688-93.
30. The AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). American Heart Journal 2011;161(3):471-7.
31. The AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. American Heart Journal 2011;161(3):538-43.
32. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010;121(2):306-14.
33. Chan KL, Teo K, Tam J, Dumesnil JG, Astronomer Investigators. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. American Heart Journal 2007;153(6):925-31.
34. Caramelli B, Durazzo A, Ikeoka D, De Bernoche C, Monachini M, Puech Leao P, et al. Short-term treatment with atorvastatin for prevention of cardiac complications after vascular surgery [abstract no:086]. Atherosclerosis Supplements 2002; Vol. 3:83.
35. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364(9435):685-96.
36. Colhoun HM, Thomason MJ, Mackness MI, Maton SM, Betteridge DJ, Durrington PN, et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabetic Medicine 2002;19(3):201-11.
37. ChiCTR-TNRC-08000263. The study of the intervention with statin on PE and CTEPH. http://apps.who.int/trialsearch/Trial.aspx?TrialID=ChiCTR-TNRC-08000263.
38. Schouten O, Hoeks SE, Voute MT, Boersma E, Verhagen HJ, Poldermans D. Long-term benefit of perioperative statin use in patients undergoing vascular surgery: Results from the DECREASE III trial. Journal of Vascular Surgery 2011;53(6):20S-1S.
39. Doggen CJ, Lemaitre RN, Smith NL, Heckbert SR, Psaty BM. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. Journal of Thrombosis and Haemostasis 2004;2(5):700-1.
40. Baylor College of Medicine. Effectiveness of intensive lipid modification medication in preventing the progression of peripheral arterial disease (The ELIMIT Study). http://clinicaltrials.gov/show/NCT00687076.
41. Brunner G, Yang EY, Kumar A, Sun W, Virani SS, Negi SI, et al. The effect of lipid modification on peripheral artery disease after endovascular intervention trial (ELIMIT). Atherosclerosis 2013;231(2):371-7.
42. Saunders J, Nambi V, Kimball KT, Virani SS, Morrisett JD, Lumsden AB, et al. Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. Journal of Vascular Surgery 2011;53(3):668-75.
43. Ge YY, Cheng JQ, Xi WJ, Xu Y, Kang YM. Effects of ulinastatin on coagulation function and deep vein thrombosis in patients undergoing hip joint replacement. Zhonghua Wai Ke Za Zhi 2011;49(9):816-9.
44. Haak E, Abletshauser C, Weber S, Goedicke C, Martin N, Hermanns N, et al. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. Atherosclerosis 2001;155(2):395-401.
45. Herrington DM, VittinghoffE, Lin F, Fong J, Harris F, Hunninghake D, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002;105(25):2962-7.
46. Armitage J, Landmesser U. HPS2-THRIVE: Treatment of HDL to reduce the incidence of vascular events. ESC Congress 2012. http://www.escardio.org/congresses/esc-2012/congress-reports/Pages/709-4-HPS2-THRIVE.aspx#.VCQj0Y2t-p0.
47. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal 2013;34(17):1279-91.
48. Li J, Landray MJ, Collins R, Armitage J, Baigent C, Chen Z, et al. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal 2013;34(17):1279-91.
49. Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine 2007;167(9):935-43.
50. Jeong HC, Ahn Y, Hong YJ, Kim JH, Jeong MH, Kim YJ, et al. Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein. International Journal of Cardiology 2013;167(5):1848-53.
51. Lacut K, Oger E, Le Gal G, Couturaud F, Louis S, Leroyer C, et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundamental and Clinical Pharmacology 2004;18(4):477-82.
52. Lacut K, Le Gal G, Abalain JH, Mottier D, Oger E. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?. Thrombosis Research 2008;122(3):314-9.
53. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010;74(12):956-64.
54. Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, et al. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimer's & Dementia 2008;4(2):145-53.
55. Liu B, Cao HM, Li GY, Liu M, Feng J, Li J, et al. Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis. Journal of International Medical Research 2011;39(6):2314-22.
56. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368(9542):1155-63.
57. Crouse JR 3rd, Grobbee DE, O'Leary DH, Bots ML, Evans GW, Palmer MK, et al. Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the METEOR study. Cardiovascular Drugs and Therapy 2004;18(3):231-8.
58. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297(12):1344-53.
59. Università degli Studi dell'Insubria. The effect of satins on d-dimer levels in patients with a previous venous thromboembolic event. http://clinicaltrials.gov/ct2/show/NCT00437892.
60. Hoshina K, Nemoto M, Hashimoto T, Miura S, Urabe G, Nakazawa T, et al. Study Design of PROCEDURE Study. A randomized comparison of the dose-dependent effects of pitavastatin in patients with abdominal aortic aneurysm with massive aortic atheroma: prevention of cholesterol embolization during endovascular and open aneurysm repair with pitavastatin (PROCEDURE) study. Annals of Vascular Disiseases 2013;6(1):62-6.
61. Freeman DJ, Robertson M, Brown EA, Rumley A, Tobias ES, Frölich M, et al. Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). BMC Geriatrics 2011;11:8.
62. Ramcharan AS, van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJ. HMG-CoA-reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. Journal of Thrombosis and Haemostasis 2009;7(4):514-20.
63. Macchia A, Laffaye N, Comignani PD, Cornejo Pucci E, Igarzabal C, Scazziota AS, et al. Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial. PLoS One 2012;7(3):e32894.
64. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Archives of Internal Medicine 2001;161(11):1405-10.
65. Rosen JB, Jimenez JG, Pirags V, Vides H, Hanson ME, Massaad R, et al. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diabetes and Vascular Disease Research 2013;10(3):277-86.
66. Shai A, Rennert HS, Rennert G, Sagi S, Leviov M, Lavie O. Statins, aspirin and risk of thromboembolic events in ovarian cancer patients. Gynecologic Oncology 2014;133(2):304-8.
67. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. British Journal of Clinical Pharmacology 2009;67(1):99-109.
68. Stangier J, Rathgen K, Stahle H, Reseski K, Kornicke T, Roth W. Co-administration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. American Journal of Cardiovascular Drugs 2009;9(1):59-68.
69. Sørensen HT, Horvath-Puho E, Søgaard KK, Christensen S, Johnsen SP, Thomsen RW, et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. Journal of Thrombosis and Haemostasis 2009;7(4):521-8.
70. van der Loo B, Spring S, Koppensteiner R. High-dose atorvastatin treatment in patients with peripheral arterial disease: effects on platelet aggregation, blood rheology and plasma homocysteine. Clinical Hemorheology and Microcirculation 2011;47(4):241-51.
71. West AMA. Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance 2010:192.
72. Yang CC, Jick SS, Jick H. Statins and the risk of idiopathic venous thromboembolism. British Journal of Clinical Pharmacology 2002;53(1):101-5.
73. Yale University. High-Dose Periop Statins for Prevention of DVT. http://clinicaltrials.gov/show/NCT00259662 (accessed November 2014).
74. Hallym University Medical Center. Rosuvastatin for Preventing Deep Vein Thrombosis (STOP-DVT). http://clinicaltrials.gov/ct2/show/results/NCT01021488 November 25, 2009.
75. Park WJ, Jo SH, Kim SA, Kim HS, Han SJ, Choi YJ, Rhim CY. Rationale and design of STOP DVT study: rosuvastatin for the prevention of deep vein thrombosis in patients undergoing total knee replacement arthroplasty - a prospective randomized open-label controlled trial. Contemporary Clinical Trials 201;32(5):779-82.
76. Hallym University Medical Center. Re-STOP DVT: Reload of high dose atorvastatin for preventing deep vein thrombosis in statin users. http://www.clinicaltrials.gov/ct2/show/NCT01063426 (accessed November 2014).
77. University of Vermont. Detecting the impact of statin therapy on lowering risk of venous thrombo-embolic events (DISOLVE). http://clinicaltrials.gov/ct2/show/NCT01524653 (accessed November 2014).
78. Agarwal V, Phung OJ, Tongbram V, Bhardwaj A, Coleman CI. Statin use and the prevention of venous thromboembolism: A meta-analysis. International Journal of Clinical Practice 2010;10:1375-83.
79. Albert MA, Danielson E, Rifai N, Ridker PM. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286(1):64-70.
80. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Journal of the American College of Cardiology 2001;37(3):973.
81. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Krstic G, Wetterslev J, et al. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD007469.pub2]
82. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61(8):763-9.
83. Buller HR, Sohme M, Middledorp S. Treatment of venous thromboembolism. Journal of Thrombosis and Haemostasis 2005;3(8):1554-60.
84. Chapman NH, Brighton T, Harris MF, Caplan GA, Braithwaite J, Chong BH. Venous thromboembolism - management in general practice. Australian Family Physician 2009;38(1-2):36-40.
85. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacology and Therapeutics 1999;84(3):413-28.
86. Diuguid DL. Choosing a parenteral anticoagulant agent. New England Journal of Medicine 2001;345(18):1340-2.
87. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279(6):458-62.
88. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):381-453.
89. Goldhaber SZ. Pulmonary embolism. Lancet 2004;363(9417):1295-305.
90. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Annals of Internal Medicine 2000;132(9):689-96.
91. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
92. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93.
93. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Archives of Internal Medicine 2002;162(11):1245-8.
94. Heit JA, Cohen AT, Anderson FA, on behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood ASH Annual Meeting 2005;106:Abstract 910.
95. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
96. Ho WK, Hankey GJ, Eikelboom JW. The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. Medical Journal of Australia 2008;189(3):144-7.
97. Kaba NK, Francis CW, Moss AJ, Zareba W, Oakes D, Knox KL, et al. Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction. Journal of Thrombosis and Haemostasis 2004;2(5):718-25.
98. Lippi G, Favaloro EJ, Sanchis-Gomar F. Venous thrombosis associated with HMG-CoA reductase inhibitors. Seminars in Thrombosis and Hemostasis 2013;39(5):515-32.
99. Pai M, Evans NS, Shah SJ, Green D, Cook D, Crowther MA. Statins in the prevention of venous thromboembolism: A meta-analysis of observational studies. Thrombosis Research 2011;128(5):422-30.
100. Rahimi K, Bhala N, Kamphuisen P, Emberson J, Biere-RafiS, Krane V, et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Medicine 2012;9(9):e1001310.
101. Raju NC, Hirsh J, Eikelboom JW. Duration of anticoagulant therapy for venous thromboembolism. Medical Journal of Australia 2009;190(12):659-60.
102. Ray JG, Rosendaal FR. The role of dyslipidemia and statins in venous thromboembolism. Current Controlled Trials in Cardiovascular Medicine 2001;2(4):165-70.
103. Ray JG. Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment. Current Opinion in Pulmonary Medicine 2003;9(5):378-84.
104. Rodriguez AL, Wojcik BM, Wrobleski SK, Myers DD, Wakefield TW, Diaz JA. Statins, inflammation and deep vein thrombosis: A systematic review. Journal of Thrombosis and Thrombolysis 2012;33(4):371-82.
105. Squizzato A, Galli M, Romualdi E, Dentali F, Kamphuisen PW, Guasti L, et al. Statins, fibrates, and venous thromboembolism: A meta-analysis. European Heart Journal 2010;31(10):1248-56.
106. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. Available from www.ctu.dk/tsa 2011:1-115.
107. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va initiation. Circulation 2001;103(18):2248-53.
108. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arteriosclerosis, Thrombosis, and Vascular Biology 2005;25(2):287-94.
109. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
110. Li L, Sun T, Zhang P, Tian J, Yang K. Statins for primary prevention of venous thromboembolism. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD008203.pub2]